Sotagliflozin

Sotagliflozin is an inhibitor of sodium-glucose cotransporters (SGLTs, IC50s = 36 and 1.8 nM for human SGLT1 and SGLT2, respectively). It increases plasma glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) levels, as well as glucose levels in the small intestine, cecum, and colon, in mice when administered at a dose of 60 mg/kg. Sotagliflozin (2 and 30 mg/kg) decreases blood glucose levels in a mouse model of diabetes induced by cyclophosphamide (Cay-13849). Formulations containing sotagliflozin have been used in the treatment of type 1 diabetes.Formal Name: methyl 5S-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-beta-L-xylopyranoside. CAS Number: 1018899-04-1. Synonyms: LP 802034, LX4211. Molecular Formula: C21H25ClO5S. Formula Weight: 424.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml. lambdamax: 224, 275 nm. SMILES: ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](SC)O1)=C2)=C2CC3=CC=C(OCC)C=C3. InChi Code: InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1. InChi Key: QKDRXGFQVGOQKS-CRSSMBPESA-N.